Curcumin for Breast Cancer

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Medical University of South Carolina

Must not be taking: Anticoagulants, Platelet inhibitors, others

Disqualifiers: Neoadjuvant therapy, Kidney disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 56 days

22 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing if taking curcumin, a substance found in turmeric, by mouth can cause changes in breast cancer cells. It focuses on patients with primary breast tumors. The researchers want to see if curcumin can help kill these cancer cells and stop them from growing. Curcumin, the active component of turmeric, has been extensively studied for its anticancer properties, including inhibiting tumor growth and inducing cancer cell death.

Research Team

Nancy DeMore, MD, FACS

Principal Investigator

Medical University of South Carolina

Eligibility Criteria

This trial is for adults with invasive breast cancer (stages I-III) who can consent to the study, have a performance status indicating they are fully active or restricted in physically strenuous activity but ambulatory, and have adequate organ function. They must be scheduled for surgery within 5-56 days from starting the trial and agree to use approved birth control if of childbearing potential.

Inclusion Criteria

My blood and organs are functioning well.

I understand the risks and benefits of the study and can give my consent.

I can provide at least 6 unstained slides for testing.

Exclusion Criteria

I am currently receiving chemotherapy or hormone therapy before surgery.

I am not taking any medications listed under the MSKCC's herb-drug interactions section.

I have issues like bile duct obstruction, gallstones, kidney stones, stomach ulcers, or acid reflux.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive curcumin at 500mg by mouth twice a day from the time surgical resection is scheduled until the night before surgical resection

Up to 56 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Curcumin

Trial Overview The study tests whether taking curcumin orally causes changes in primary breast cancer tumors before surgery. Participants will receive curcumin supplements and researchers will observe any biological effects on their tumor tissue.

Participant Groups

Group I: Curcumin Experimental Treatment 1 Intervention

Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.

Curcumin is already approved in United States, European Union, India, China for the following indications:

Approved in United States as Curcumin for:

• Dietary Supplement

Approved in European Union as Curcuma for:

• Herbal Medicinal Product

Approved in India as Haldi for:

• Traditional Medicine

Approved in China as Jiang Huang for:

• Traditional Chinese Medicine

Who Is Running the Clinical Trial?

Medical University of South Carolina

Lead Sponsor

Trials

994

Recruited

7,408,000+